Prevention of Breast Cancer-Related Arm Lymphoedema (BCRAL)

Publication Date: February 1, 2024
Last Updated: February 29, 2024

Summary of Recommendations

Risk factors for breast cancer related arm lymphoedema

  • When there are resource constraints, patients who present with a higher BMI (BMI ≥30 kg/m2) should be prioritised over patients with BMI <30 kg/m2 when selecting patients for prophylactic management of lymphoedema.
  • The timing of chemotherapy (neoadjuvant versus adjuvant) may impact the subsequent risks of lymphoedema but should not be a major determining factor on selecting patients for prophylactic management of lymphoedema until more studies are available.
  • The type of chemotherapy (taxane versus non-taxane) a patient receives may impact the subsequent risks of lymphoedema, but should not be a major determining factor on selecting patients for prophylactic management of lymphoedema until more studies are available.
  • When there are resource constraints, patients who had ≥15 axillary lymph nodes removed in axillary dissection should be prioritised over patients who had less lymph nodes removed when selecting patients for prophylactic management of lymphoedema.
  • When there are resource constraints, patients who received axillary radiation should be prioritised over patients who receive radiation to the breast/chest wall ± the supraclavicular fossa when selecting patients for prophylactic management of lymphoedema.

Overview

Title

Prevention of Breast Cancer-Related Arm Lymphoedema (BCRAL)

Authoring Organization